Pharmacological Approaches to Modulate the Scarring Process after Glaucoma Surgery
Open Access
- 19 June 2023
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 16 (6) , 898
Abstract
Glaucoma is an acquired optic neuropathy that results in a characteristic optic nerve head appearance and visual field loss. Reducing the IOP is the only factor that can be modified, and the progression of the disease can be managed through medication, laser treatment, or surgery. Filtering procedures are used when target pressure cannot be obtained with less invasive methods. Nevertheless, these procedures require accurate control of the fibrotic process, which can hamper filtration, thus, negatively affecting the surgical success. This review explores the available and potential pharmacological treatments that modulate the scarring process after glaucoma surgery, analyzing the most critical evidence available in the literature. The modulation of scarring is based on non-steroidal anti-inflammatory drugs (NSAIDs), mitomycin, and 5-fluorouracil. In the long term, the failure rate of filtering surgery is mainly due to the limitations of the current strategies caused by the complexity of the fibrotic process and the pharmacological and toxicological aspects of the drugs that are currently in use. Considering these limitations, new potential treatments were investigated. This review suggests that a better approach to tackle the fibrotic process may be to hit multiple targets, thus increasing the inhibitory potential against excessive scarring following surgery.Keywords
This publication has 37 references indexed in Scilit:
- The Interaction of Nepafenac and Prostaglandin Analogs in Primary Open-angle Glaucoma PatientsJournal of Glaucoma, 2016
- Topical infliximab for the suppression of wound healing following experimental glaucoma filtration surgeryDrug Design, Development and Therapy, 2014
- Beta radiation for glaucoma surgeryCochrane Database of Systematic Reviews, 2012
- The role of different VEGF isoforms in scar formation after glaucoma filtration surgeryExperimental Eye Research, 2011
- SiRNA delivery with exosome nanoparticlesNature Biotechnology, 2011
- A Phase III Study of Subconjunctival Human Anti–Transforming Growth Factor β2 Monoclonal Antibody (CAT-152) to Prevent Scarring after First-Time TrabeculectomyOphthalmology, 2007
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trialThe Lancet, 1999
- Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA PolymeraseScience, 1990
- Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro.Proceedings of the National Academy of Sciences, 1986